Compounded GLP-1 & Peptides in 2026: What's Legal, What Changed

Why this page exists, and why it has a date on it

The legal status of compounded GLP-1 drugs and peptides has changed more in the last eighteen months than in the decade before it, and most of what's written online is either out of date or sold by someone with a stake in a particular answer. This page is our attempt at a straight, dated read of where things actually stand, and because it decays fast, the last-reviewed date at the top is load-bearing. If you're reading this well after that date, treat the specifics as a starting point to verify, not gospel.

The reason a payments company maintains a regulatory tracker at all is simple: whether a product is legal, and under what model, is the first thing that determines whether it can be boarded for card processing. So this isn't academic for us. It's the front of the underwriting conversation.

The shortage era is over

The single biggest change is that the drug shortages that powered mass compounding have officially ended. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. That matters because federal law lets compounders make copies of an FDA-approved drug largely when that drug is in shortage. Once the shortage is declared over, that broad permission winds down.

The most consequential effect fell on 503B outsourcing facilities, which had been compounding semaglutide and tirzepatide at scale during the shortage. With the shortages resolved, that high-volume lane closed, and the FDA set wind-down expectations for facilities that had been relying on it. The flood of inexpensive compounded GLP-1 that defined 2023–2024 is not coming back through that door.

What survives: narrower 503A compounding

Patient-specific compounding under 503A, a licensed pharmacy preparing a medication for an individual patient pursuant to a valid prescription, was not eliminated. It remains permitted where there's a genuine clinical basis: a documented allergy to an inactive ingredient in the approved product, a need for a dose or form the manufacturer doesn't make, and similar individualized reasons. What it is not is a workaround to keep selling off-brand semaglutide to anyone who fills out a web form. The lane is real but narrow, and “narrow” is exactly how underwriters and regulators now read it.

The distinction that matters in 2026 is between a legitimate, prescription-driven, clinically-justified compounding model and a shortage-era volume model wearing its clothes. The first is a defensible business. The second is a terminated merchant account waiting to happen.

The two developments to watch

Two pending items could tighten things further, and both were live as of this page's review date.

The first is the FDA's 503B bulks-list proposal, announced April 30, 2026 with a public comment period running through June 29, 2026. The 503B bulks list governs which bulk drug substances outsourcing facilities may compound from; the proposal would leave semaglutide, tirzepatide, and liraglutide off that list, formalizing the exclusion of GLP-1 substances. If finalized as written, it would further constrain the bulk-substance pathway for these products. Because it's a proposal under active comment as of this review date, nothing is final, but the direction of travel is restrictive, and prudent models plan for the stricter outcome.

The second is a forthcoming FDA peptide advisory expected at a July 2026 advisory-committee meeting, addressing certain peptide bulk substances that are not found in FDA-approved drugs. Industry coverage points to performance- and recovery-marketed peptides (compounds such as MOTS-C, discussed for obesity, among others) as likely subjects. The outcome could limit which peptides can be compounded at all. As of the review date it's anticipated, not concluded, so we flag it as a development rather than a rule.

We track both because peptide and GLP-1 regulatory freshness is precisely the kind of thing thin competitor pages get wrong, they wrote once and never updated.

FDA enforcement and the Medicare expansion

Two 2026 developments beyond the bulks-list proposal have reshaped the operating environment for GLP-1 telehealth. The first is escalated FDA enforcement. In September 2025 the FDA issued more than 55 warning letters to online sellers of compounded semaglutide, targeting businesses marketing the product directly to consumers without the clinical gating that distinguishes a pharmacy model from a volume play. A second wave of letters followed in June 2026, again focused on consumer-facing promotion of compounded GLP-1 products. The pattern is clear: the FDA is actively pushing non-compliant sellers out of the market, and the remaining lane is the licensed-pharmacy, Rx-model path.

The second is the Medicare Part D expansion. Starting July 1, 2026, Medicare began covering GLP-1 medications for weight management at a $50 monthly cap for Part D beneficiaries. That compresses the price ceiling for direct-to-consumer telehealth programs that had been selling compounded or branded GLP-1s at $99–$348 a month. Programs competing on price alone are losing ground to the pharmacy benefit; programs competing on access, clinical quality, and a compliant Rx model are the ones that remain both viable and boardable. For underwriting, the signal is that the regulatory and competitive floor keeps rising, and a merchant whose model depends on anything other than licensed prescribers and genuine patient evaluation is a risk no responsible sponsor will carry.

What this means for your merchant account

Here is the part that connects all of the above to whether you can actually process payments. Underwriting for this vertical keys off your model, and in 2026 the models sort cleanly:

• Licensed-pharmacy and legitimate Rx programs, telehealth that connects patients to licensed prescribers, dispensing through licensed pharmacies, with real clinical gating, remain underwritable. These are the programs we board, as approved by underwriting.
• Shortage-dependent volume models, anything that only worked because the branded drug was scarce, are not boardable now that the shortage is resolved.
• Research-only peptides sold as treatments, products marketed with health or performance claims they aren't approved to make, are a compliance and chargeback problem no responsible processor will take.

What underwriting examines is concrete: your sourcing and pharmacy relationships, your prescriber model and clinical gating, your LegitScript certification where it applies, and the claims you make in your marketing. A clean, prescription-anchored model with the right certifications is boardable; a model that depends on a closed lane or aggressive claims is not. The full mechanics live on our peptides, GLP-1 & telehealth page, and the certification path is covered in the LegitScript guide.

The bottom line

Compounded GLP-1 is still legal in the narrow, patient-specific sense, and legitimate telehealth-Rx programs continue to operate, but the easy, shortage-fueled version of this business is over, and the pending FDA actions point toward more restriction, not less. For payments, that means the bar to board is higher and the questions are sharper, which is exactly why a processor that underwrites this vertical properly is worth more than one that boards anyone and disappears when the FDA moves.

If you run a compliant, licensed-pharmacy or Rx-model program and want processing that understands this landscape, request a consultation. And check back, we review this page monthly, because in this vertical, last month's answer is not this month's.